In a randomised, double-blind study, a transdermal patch containing either hyoscine or placebo was applied post-auricularly in 190 adult patients under 65 years old, seven to twelve hours prior to their undergoing minor orthopaedic or plastic surgery under thiopentone/nitrous oxide/ halothane general anaesthesia. In the first 24 hours after surgery 34% of patients vomited. The incidence of nausea (31 % vs 54%; P < 0.01) and the number of episodes of vomiting (66 vs 125; P < 0.05) during the first 24 hours were significantly less with hyoscine than with placebo. The hyoscine group required fewer doses of antiemetic than the placebo group (12 vs 27; P < 0.05).
therapeutic levels for approximately sixty hours, thus avoiding the high peak levels and the rapid clearance after oral or parenteral administration.
Therefore we have assessed the efficacy of transdermal hyoscine (given preoperatively as Scopoderm) (Ciba-Geigy) compared to placebo in reducing the incidence of nausea and vomiting following minor surgery, METHODS Patient selection:
The study was approved by the Canterbury Hospital Board Ethical Committee. Informed consent was obtained from 221 AS.A grade 1-2 patients having elective plastic surgical or orthopaedic procedures of less than two hours' duration. Patients were selected to be between the ages of 16 and 65 years, weighed between 40 and 100 kilograms and had no history of gastro-oesophageal reflux or regular anti emetic or anticholinergic medication. Identical, unlabelled patches containing either hyoscine or placebo were supplied by Ciba-Geigy (NZ) Ltd. Random number lists were used to assign patients to one of two treatment groups, and a sealed enveloped containing the trial medication, either Scopoderm or a placebo patch, was allocated for each patient. Sexes were randomised separately, with equal numbers of males and females in each group and the trial was conducted using a double-blind technique.
Clinical management:
Patients were interviewed prior to surgery and any previous history of vomiting with anaesthesia and/or motion sickness were recorded. The transdermal patches were placed on the post-auricular skin at 2300 hours on the preceding night for morning cases or at 0630 hours on the day of surgery for afternoon cases (i.e. seven to twelve hours prior to surgery).
Approximately one hour preoperatively opioid premedication (morphine 10-15 mg or omnopon 15-20 mg) was given intramuscularly. The presence or absence of restlessness, sedation, symptoms of nausea or vomiting and dryness of mouth were assessed immediately prior to premedication and to induction of anaesthesia. Induction was achieved with thiopentone and then anaesthesia was maintained with halothane, nitrous oxide and oxygen, using a circle system with the patient breathing spontaneously from a mask. Patients were not intubated. The patches remained in place for 48 hours after surgery.
Opioids (morphine or omnopon) or oral analgesics were given for postoperative pain relief as indicated and an antiemetic, (metoclopramide or prochlorperazine) was administered at the patient's request. No patient was given additional prophylactic antiemetic cover.
Postoperative assessment:
Postoperative assessment of vital signs, the presence or absence of drowsiness, restlessness, dryness of mouth, and nausea were made at intervals by nursing staff in the recovery room and ward at the same times as routine postoperative nursing observations, initially half-hourly and then at increasing intervals. The occurrence of vomiting since the previous observation was recorded.
In addition to this, all patients were carefully interviewed either personally or by telephone by a trained independent observer (A W) at 24 and 48 hours after surgery. Details of the presence and severity of nausea, episodes of vomiting, the degree of dry mouth experienced and the times and doses of all drugs given postoperatively were confirmed.
Statistics:
The study size was designed to detect a reduction in the incidence of vomiting in the hyoscine group to two-thirds that found in the placebo group, and was based on the results of a power analysis 3 that incorporated data from previous clinical reports and a pilot study of transdermal hyoscine conducted in our hospital.
Statistical comparisons between the two groups were made using Chi-squared and Student's t tests as appropriate. A probability level of 0.05 or less was considered significant.
Survival analysis was performed using the BMDP computer package 4 to compare treatment groups with the time relationships between patch application and various aspects of clinical managment such as the start of surgery.
RESULTS
Of the 221 patients entering the trial, 31 were subsequently excluded for the reasons outlined in Table 1 . In the remaining 190 patients, there were no demographic differences between the two treatment groups, each of 95 subjects, excepting that the hyoscine group contained more individuals with a past history of motion sickness (P < 0.05). Survival analysis showed no significant difference between the two groups with respect to the time relationships between patch application and surgery or other aspects of clinical management tested for, such as duration of anaesthetic and length of stay in the recovery ward.
The overall incidence of vomiting in the first 24 hours was 34%. The incidences of nausea and vomiting for this period in the hyoscine group were 31 % and 28% respectively, and for the placebo group 54% and 40%. For the second 24 hours, the incidences of nausea and vomiting in the hyoscine group were 11 % and 1 % respectively and 19% and 3% for the placebo group. The results are summarised in Table 2 .
The incidences of nausea in the first 24 hours after surgery was significantly less in the hyoscine group than in the placebo group (P < 0.01). Likewise the number of episodes of vomiting was less (P < 0.05). However, normalising with respect to the number of patients who vomited in each group (i.e. a mean of 3.5 episodes per patient who vomited in the placebo group and 2.7 episodes in the hyoscine group) failed to demonstrate a significant difference between groups. The hyoscine group required fewer doses of anti emetic than the placebo group (P < 0.05).
The differences for the second 24 hours were not statistically significant. Patients in the hyoscine group were more likely to have a dry mouth at the time of premedication (P < 0.05) and at induction (P < 0.05). The frequency of other side-effects in the first 24 hours after surgery including restlessness, disorientation, postoperative dry mouth and blurred vision was low, and not significantly different between the two groups, although there was a trend to more reporting of blurred vision in the hyoscine group (0.1 > P> 0.05). There was no significant difference in opioid analgesic usage between the two groups.
In both groups, patients with a previous history of vomiting after surgery were more likely to be nauseated (P < 0.001) or to vomit (P < 0.01) in the first 24 hours after surgery than those who did not. The same was true for vomiting in the first 24 hours postoperatively for those with a history of motion sickness (P < 0.05). However, on the second postoperative day nausea and vomiting were not related to the previous history of postoperative vomiting and/or motion sickness.
DISCUSSION
Hyoscine is the most effective prophylactic antiemetic for motion sickness, and the transdermal delivery system provides prolonged action while reducing side-effects.5 It is also effective against postoperative nausea and vomiting. 6 Initial studies with transdermal hyoscine have been encouraging. In two small studies of gynaecological patients the incidence of nausea and vomiting was reduced in the first 24 hours compared to placebo, but not thereafter/,8 while in a mixed surgical group of 30 patients, transdermal hyoscine was significantly better than placebo at 20 hours postoperatively, and had fewer side-effeCts than by the intramuscular route. 9 We have found a significant reduction in nausea and vomiting with transdermal hyoscine in orthopaedic and plastic surgical patients in the first 24 hours postoperatively, comparable to these findings. However, it appears less effective in preventing vomiting. Nevertheless, the efficacy of this preparation as a postoperative antiemetic is similar to other drugs or techniques such as droperidol or metoclopramide,lo and acupuncture. II .
Both the low incidence of side-effects encountered in this study and the ease of application of the skin patch are seen as advantages of the transdermal system for drug administration. While side-effects are minimal and minor, recent reports have drawn attention to the danger of the transdermal hyoscine patch in patients at risk for' closed-angle glaucoma, in whom this technique should be avoided. 12 In addition its use should be avoided in children and the elderly.
An apparent lessening of the efficacy of the transdermal system in surgical patients after 24 hours has been reported, 8, 9 and this also appears to be the case in the present study. It has been suggested that this is due either to insufficient circulating levels of hyoscine I or to patient tolerance. 8 Unfortunately, understanding of the pharmacokinetics of transdermal hyoscine has been confined to urinary excretion studies, due to lack of a satisfactory plasma assay.
However, the overall incidence of nausea and vomiting falls rapidly after the first postoperative day, and this apparent lessening of the beneficial effects of hyoscine to a nonsignificant level may simply be a reflection of the small sample sizes used in previous studies. Even in the present larger study, the planned size of which was based on statistical power analysis utilising the reported incidences within 24 hours after surgery in previous studies, we have failed to demonstrate a reduction in the incidence of nausea and vomiting beyond the first postoperative day with transdermal hyoscine.
It may be that the mechanisms of early and late postoperative nausea and vomiting in routine minor surgery differ, and that late symptoms are largely un influenced by antiemetic medication. In our own view, however, the most plausible explanation is that this represents a Type 11 statistical error likely to be present in all but very large studies consisting of many hundreds of patients.
In the present study, there were more patients with a history of motion sickness in the hyoscine group. Since this variable predisposes to vomiting in the postoperative period, this would tend to reduce the apparent efficacy against vomiting of transdermal hyoscine in this study.
We conclude that transdermal hyoscine applied to the post-auricular skin preoperatively reduces postoperative nausea, and to a lesser extent vomiting, to a degree similar to other pharmacological agents, with minimal side-effects. However, a truly effective method of preventing these minor yet distressing symptoms has yet to be found.
